GlassScriptPhysician profile
Mackenzie Brynn Hoffman
NPI 1821641002
$1,453.70
in general payments reported to CMS, 2019-2025
24 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.56 · 2022: $18.21 · 2023: $184 · 2024: $447 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.86 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $156.93 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $129.92 | 2021-2025 | Trelegy Ellipta |
| Insulet Corporation | $114.88 | 2025 | Omnipod |
| Abbvie INC. | $111.88 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.87 | 2023-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $70.56 | 2024-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $59.58 | 2023-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $57.87 | 2023-2025 | Veozah |
| Lundbeck LLC | $55.44 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.07 | 2025 | Caplyta |
| Eisai INC. | $52.61 | 2021-2025 | |
| Pfizer INC. | $49.19 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.68 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $41.09 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $27.04 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $24.70 | 2024 | |
| Scilex Pharmaceuticals INC. | $20.92 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.68 | 2025 | Hetlioz, Fanapt |
| Xeris Pharmaceuticals, INC. | $16.60 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2025 | |
| Cequr Corporation | $15.57 | 2024 | Cequr Simplicity |
| Amgen INC. | $13.65 | 2024 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $13.18 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.